Apogee Therapeutics reports the first data on the drug in long -term eczema

Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.

Apogee Therapeutics said on Monday that his experimental treatment on antibodies attenuated signs and symptoms of atopic dermatitis, a current inflammatory skin condition, much more than a placebo – achieving the effective objectives of a mid -term clinical trial.

In a side by side comparison, the APOGEE medication, called APG777, has shown similar skin clariance compared to two antibodies already on the market: Sanofi and Regeneron’s Dupixent and Ebglyss of Eli Lilly.

APG777 was designed to be injected quarterly or twice a year, which, if proven in subsequent clinical trials, would make it more practical than the injections of twice and monthly required for its competitors.